One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2019-121521
Copy DOI Journal: Blood |  Publication Date: Nov 13, 2019 |
 Citations: 6 |
Affiliation: University of Manchester, Manchester Academic Health Science Centre, The University of Texas MD Anderson Cancer Center, AbbVie (United States), Pharmacyclics (United States), Ghent University Hospital, Universitair Ziekenhuis Brussel, Levine Cancer Institute, Cliniques Universitaires Saint-Luc, University of Tennessee Health Science Center, University of Tennessee at Knoxville, Royal Marsden NHS Foundation Trust, King's College Hospital, Cornell University, Cancer Research UK, Universitair Ziekenhuis Leuven, University of California, Los Angeles, University College Hospital, University College London, St James's University Hospital, Vanderbilt University, Hackensack University Medical CenterPhase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
